Wang Qianyan, Wei Lei, Chen Guanghui, Chen Qiang
Liyuan Cardiovascular Center, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Pharmacy, Tianmen Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Chinese Medicine, Tianmen, China.
Front Pharmacol. 2025 Apr 16;16:1490480. doi: 10.3389/fphar.2025.1490480. eCollection 2025.
This review provides an in-depth exploration of the potential of Ginsenoside Rg1 in the treatment of Parkinson's disease (PD). The emphasis of this article was the therapeutic mechanisms of Rg1, which involved the reduction of inflammation, antioxidant properties, support for neuronal survival and regeneration, regulation of cellular energy processes, and enhancement of autophagic pathways. Rg1 may protect neurons and improve both motor and cognitive impairments associated with PD through multiple mechanisms. However, challenges exist in the clinical application of Rg1, such as low bioavailability as well as a lack of comprehensive long-term safety and efficacy data. This article also reviewed network pharmacology analyses published previously to identify and explore the potential molecular targets of Rg1 in PD treatment, while evaluating strategies such as drug delivery technologies, optimizing administration routes, and combination therapies. Ultimately, this review highlights the necessity for large-scale clinical trials to validate the clinical efficacy of Rg1 and discusses its potential for PD treatment clinically.
本综述深入探讨了人参皂苷Rg1在治疗帕金森病（PD）方面的潜力。本文重点关注Rg1的治疗机制，包括减轻炎症、抗氧化特性、支持神经元存活和再生、调节细胞能量过程以及增强自噬途径。Rg1可能通过多种机制保护神经元并改善与PD相关的运动和认知障碍。然而，Rg1的临床应用存在挑战，例如生物利用度低以及缺乏全面的长期安全性和有效性数据。本文还回顾了先前发表的网络药理学分析，以确定和探索Rg1在PD治疗中的潜在分子靶点，同时评估药物递送技术、优化给药途径和联合疗法等策略。最终，本综述强调了进行大规模临床试验以验证Rg1临床疗效的必要性，并讨论了其在PD临床治疗中的潜力。
